(CYBR) CyberArk Software - Overview
Stock: Privileged Access, Identity Security, Secrets Management, Zero Trust
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 52.7% |
| Relative Tail Risk | -7.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -10.11 |
| Character TTM | |
|---|---|
| Beta | 1.103 |
| Beta Downside | 1.127 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.88% |
| CAGR/Max DD | 1.51 |
Description: CYBR CyberArk Software December 17, 2025
CyberArk Software Ltd. (NASDAQ:CYBR) provides a portfolio of identity-security solutions, ranging from privileged-access management (Privileged Access Manager, Privilege Cloud) and secure remote access to workforce authentication (adaptive MFA, SSO) and machine-identity protection (Conjur, Venafi). Its offerings are delivered primarily as SaaS, targeting high-risk environments such as financial services, healthcare, and government agencies.
In FY 2024 the company reported revenue of roughly **$1.1 billion**, a **~14 % year-over-year increase**, with subscription revenue accounting for about **85 %** of total sales and an **annual churn rate near 5 %**-both metrics that signal strong recurring revenue dynamics in the privileged-access-management (PAM) market.
Key macro drivers include the accelerating shift to cloud workloads (global cloud-services spend is projected to grow at **~19 % CAGR** through 2027) and heightened regulatory scrutiny on data-access controls, which together expand the addressable market for PAM solutions-estimated at **$15 billion** and growing at **~10 % annually**.
CyberArk’s competitive positioning is reinforced by its **CORA AI** engine for automated credential rotation and its integration with major CSPs (AWS, Azure, GCP), helping customers reduce attack surface while meeting compliance mandates.
For a deeper quantitative comparison of CyberArk’s valuation metrics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -146.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.21 > 1.0 |
| NWC/Revenue: 73.01% < 20% (prev 38.58%; Δ 34.42% < -1%) |
| CFO/TA 0.06 > 3% & CFO 286.7m > Net Income -146.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.6m) vs 12m ago 5.15% < -2% |
| Gross Margin: 77.42% > 18% (prev 0.79%; Δ 7663 % > 0.5%) |
| Asset Turnover: 33.34% > 50% (prev 29.89%; Δ 3.45% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 0.95
| A: 0.21 (Total Current Assets 1.99b - Total Current Liabilities 992.9m) / Total Assets 4.82b |
| B: -0.06 (Retained Earnings -273.6m / Total Assets 4.82b) |
| C: -0.02 (EBIT TTM -69.1m / Avg Total Assets 4.08b) |
| D: -0.10 (Book Value of Equity -250.4m / Total Liabilities 2.41b) |
| Altman-Z'' Score: 0.95 = BB |
Beneish M -3.03
| DSRI: 0.84 (Receivables 373.8m/328.5m, Revenue 1.36b/1.00b) |
| GMI: 1.02 (GM 77.42% / 79.17%) |
| AQI: 0.91 (AQ_t 0.58 / AQ_t-1 0.64) |
| SGI: 1.36 (Revenue 1.36b / 1.00b) |
| TATA: -0.09 (NI -146.9m - CFO 286.7m) / TA 4.82b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of CYBR shares?
Over the past week, the price has changed by -4.22%, over one month by -10.40%, over three months by -20.15% and over the past year by +4.94%.
Is CYBR a buy, sell or hold?
- StrongBuy: 28
- Buy: 8
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CYBR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 474.8 | 16% |
| Analysts Target Price | 474.8 | 16% |
| ValueRay Target Price | 489.4 | 19.6% |
CYBR Fundamental Data Overview February 10, 2026
P/S = 14.5288
P/B = 8.2275
P/EG = 4.7433
Revenue TTM = 1.36b USD
EBIT TTM = -69.1m USD
EBITDA TTM = -1.36m USD
Long Term Debt = 1.22b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 599.2m USD (from netDebt column, last quarter)
Enterprise Value = 19.46b USD (19.78b + Debt 1.22b - CCE 1.54b)
Interest Coverage Ratio = unknown (Ebit TTM -69.1m / Interest Expense TTM 0.0)
EV/FCF = 75.04x (Enterprise Value 19.46b / FCF TTM 259.3m)
FCF Yield = 1.33% (FCF TTM 259.3m / Enterprise Value 19.46b)
FCF Margin = 19.05% (FCF TTM 259.3m / Revenue TTM 1.36b)
Net Margin = -10.79% (Net Income TTM -146.9m / Revenue TTM 1.36b)
Gross Margin = 77.42% ((Revenue TTM 1.36b - Cost of Revenue TTM 307.3m) / Revenue TTM)
Gross Margin QoQ = 83.31% (prev 76.61%)
Tobins Q-Ratio = 4.04 (Enterprise Value 19.46b / Total Assets 4.82b)
Interest Expense / Debt = 0.13% (Interest Expense 1.57m / Debt 1.22b)
Taxrate = 21.0% (US default 21%)
NOPAT = -54.6m (EBIT -69.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.00 (Total Current Assets 1.99b / Total Current Liabilities 992.9m)
Debt / Equity = 0.51 (Debt 1.22b / totalStockholderEquity, last quarter 2.40b)
Debt / EBITDA = -439.3 (out of range, set to none) (Net Debt 599.2m / EBITDA -1.36m)
Debt / FCF = 2.31 (Net Debt 599.2m / FCF TTM 259.3m)
Total Stockholder Equity = 2.37b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.60% (Net Income -146.9m / Total Assets 4.82b)
RoE = -6.20% (Net Income TTM -146.9m / Total Stockholder Equity 2.37b)
RoCE = -1.92% (EBIT -69.1m / Capital Employed (Equity 2.37b + L.T.Debt 1.22b))
RoIC = -1.72% (negative operating profit) (NOPAT -54.6m / Invested Capital 3.17b)
WACC = 9.40% (E(19.78b)/V(21.00b) * Re(9.98%) + D(1.22b)/V(21.00b) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.64%
[DCF Debug] Terminal Value 76.83% ; FCFF base≈243.9m ; Y1≈300.8m ; Y5≈512.4m
Fair Price DCF = 121.5 (EV 6.73b - Net Debt 599.2m = Equity 6.13b / Shares 50.5m; r=9.40% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 62.18 | EPS CAGR: -14.92% | SUE: -0.68 | # QB: 0
Revenue Correlation: 98.81 | Revenue CAGR: 33.09% | SUE: 4.0 | # QB: 7
EPS next Quarter (2026-03-31): EPS=1.14 | Chg30d=+0.018 | Revisions Net=+1 | Analysts=23
EPS current Year (2026-12-31): EPS=5.07 | Chg30d=+0.152 | Revisions Net=+7 | Growth EPS=+15.2% | Growth Revenue=+18.7%
EPS next Year (2027-12-31): EPS=6.39 | Chg30d=-0.002 | Revisions Net=+8 | Growth EPS=+26.1% | Growth Revenue=+18.2%